Burst Biologics distributed unapproved umbilical cord blood products as drugs while failing sterility and donor-screening rules.
What happened
FDA inspected Burst Biologics' Boise, Idaho facility from February 22 to March 5, 2021 and reviewed its website. FDA found the umbilical cord blood products were intended to treat diseases and were marketed without an approved biologics license or IND, and it documented significant deviations in donor screening, aseptic processing, environmental monitoring, component testing, and sterility-failure investigations.
What FDA found
The firm did not screen out donors from an area at increased risk for Zika virus.
21 CFR 1271.75(d)(1)The firm did not properly validate the aseptic process used to make products claimed to be sterile.
21 CFR 211.113(b)The firm's environmental and personnel monitoring was inadequate, and excursions were not investigated.
21 CFR 211.42(c)(10)(iv)The firm used components in manufacturing without sampling, testing, or quality release first.
21 CFR 211.84(a)The firm did not thoroughly investigate sterility failures in its batches.
21 CFR 211.192The firm marketed its umbilical cord blood products as drugs without an approved biologics license or an IND.
42 U.S.C. 262(a); 21 U.S.C. 355(i)
What FDA wants
FDA asks the company to respond in writing within 15 working days with specific corrective steps and supporting documentation, or explain why it cannot complete the actions within that time and give a completion timeframe.
Who should pay attention
- clinics and providers administering cord blood products
- distributors or buyers of BioBurst products
- manufacturers of allogeneic HCT/Ps
This is a summary. Read the original letter on fda.gov.